Vascular endothelial growth factor inhibitors (anti-VEGF) use in Nigeria: The way forward

Abstract

Intraocular neovascularization is a serious, blinding complication of diverse ischemic retinal vascular disorders. The treatment includes the use of vascular endothelial growth factors inhibitors (anti-VEGF), which are administered via intraocular injections. The commonly used anti-VEGF include bevacizumab, ranibizumab, and aflibercept. Although ranibizumab and aflibercept are approved for intraocular application, bevacizumab is used “off-label.” This article reviews the advantages and drawbacks of the anti-VEGF use and the implications for Nigeria where eye diseases requiring anti-VEGF treatment are also prevalent.